| |
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now. 
|
|
Today’s Big NewsDec 16, 2024 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
| By James Waldron Fierce Biotech recounts the biggest biotech blunders and one inspiring intervention in the 2024 edition of Rotten Tomatoes. |
|
|
|
By Fraiser Kansteiner Novo Nordisk is laying out 8.5 billion Danish kroner (about $1.2 billion) to establish a new manufacturing plant in Odense, Denmark, where the company eventually plans to hire on 400 permanent staffers. The modular factory will be kitted out to produce multiple drugs within rare disease indications, including hemophilia. |
By Fraiser Kansteiner Roche is discontinuing further development of Spark’s experimental hemophilia A gene therapy. A Roche spokesperson told Fierce Biotech that the company is instead introducing a new, enhanced function factor VIII hemophilia A candidate into its gene therapy pipeline. |
By Conor Hale Developed by neurosurgeons at the University of Calgary, the hybrid polymer-metal ReSolv stent slows the flow of blood to form a clot within the aneurysm. |
|
Antibody-based therapies have transformed the treatment of many diseases, with biologics remaining at the cutting-edge of R&D today. Access this insightful resource today to explore the traditional technologies used for finding antibody hits, and the latest innovations helping to overcome the top challenges with legacy methods. Download now. 
|
|
By Angus Liu Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. |
By Gabrielle Masson Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies said. |
By Kevin Dunleavy After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), Neurocrine Biosciences has scored an FDA approval for its first-in-class medicine Crenessity. |
By Darren Incorvaia Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. |
By Zoey Becker The companies have "fulfilled all regulatory closing conditions" for the pending buyout, according to a Saturday press release. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
